Abvc Biopharma Stock Alpha and Beta Analysis
| ABVC Stock | USD 2.43 0.10 4.29% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ABVC Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in ABVC Biopharma over a specified time horizon. Remember, high ABVC Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ABVC Biopharma's market risk premium analysis include:
Beta 1.69 | Alpha (0.50) | Risk 3.73 | Sharpe Ratio (0.08) | Expected Return (0.29) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out ABVC Biopharma Backtesting, ABVC Biopharma Valuation, ABVC Biopharma Correlation, ABVC Biopharma Hype Analysis, ABVC Biopharma Volatility, ABVC Biopharma History and analyze ABVC Biopharma Performance. ABVC Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ABVC Biopharma market risk premium is the additional return an investor will receive from holding ABVC Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ABVC Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ABVC Biopharma's performance over market.| α | -0.5 | β | 1.69 |
ABVC Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ABVC Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how ABVC Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.ABVC Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how ABVC Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ABVC Biopharma shares will generate the highest return on investment. By understating and applying ABVC Biopharma stock market price indicators, traders can identify ABVC Biopharma position entry and exit signals to maximize returns.
ABVC Biopharma Return and Market Media
The median price of ABVC Biopharma for the period between Tue, Sep 30, 2025 and Mon, Dec 29, 2025 is 2.85 with a coefficient of variation of 12.44. The daily time series for the period is distributed with a sample standard deviation of 0.34, arithmetic mean of 2.74, and mean deviation of 0.28. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | ABVC BioPharma Has Received a Cumulative Total of US566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus Production | 10/08/2025 |
2 | Acquisition by Smith J.b. of 40000 shares of ABVC Biopharma at 0.75 subject to Rule 16b-3 | 10/15/2025 |
3 | Real time pattern detection on ABVC BioPharma Inc. stock - Market Activity Summary Fast ExitEntry Strategy Plans - newser.com | 10/28/2025 |
4 | ABVC BioPharma Receives Additional US100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US695,950 | 10/31/2025 |
5 | ABVC BioPharma Reports 230 percent YoY Licensing Revenue Growth and 181 percent Asset Expansion in Q3 2025 | 11/03/2025 |
6 | Can ABVC BioPharma Inc. stock double in next 5 years - 2025 Trade Ideas Free Safe Capital Growth Stock Tips - fcp.pa.gov.br | 11/06/2025 |
7 | Will ABVC BioPharma Inc. stock sustain high P E ratios - 2025 Price Action Summary Risk Controlled Daily Trade Plans - newser.com | 11/11/2025 |
8 | How ABVC BioPharma Inc. stock benefits from strong dollar - IPO Watch Target Return Focused Stock Picks - newser.com | 11/14/2025 |
9 | Is ABVC BioPharma Inc. stock cheap compared to fundamentals - 2025 Institutional Moves Consistent Profit Trade Alerts - newser.com | 11/19/2025 |
10 | Acquisition by Smith J.b. of 500000 shares of ABVC Biopharma at 0.9 subject to Rule 16b-3 | 11/20/2025 |
11 | Disposition of tradable shares by King Chi-hsin Richard of ABVC Biopharma subject to Rule 16b-3 | 11/25/2025 |
12 | Acquisition by Smith J.b. of 11500 shares of ABVC Biopharma at 0.75 subject to Rule 16b-3 | 12/03/2025 |
13 | Acquisition by Ramsey Sally Judith of tradable shares of ABVC Biopharma at 80000.0 subject to Rule 16b-3 | 12/12/2025 |
14 | Can ABVC BioPharma Inc. stock hit analyst price targets - July 2025 Technicals Low Risk Growth Stock Ideas - | 12/19/2025 |
About ABVC Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ABVC or other stocks. Alpha measures the amount that position in ABVC Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 1.06 | 0.83 | 0.34 | 0.33 | Revenue Per Share | 0.31 | 0.0352 | 0.0437 | 0.0458 |
ABVC Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of ABVC Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ABVC Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ABVC Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ABVC Biopharma. Please utilize our Beneish M Score to check the likelihood of ABVC Biopharma's management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with ABVC Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out ABVC Biopharma Backtesting, ABVC Biopharma Valuation, ABVC Biopharma Correlation, ABVC Biopharma Hype Analysis, ABVC Biopharma Volatility, ABVC Biopharma History and analyze ABVC Biopharma Performance. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
ABVC Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.